What is AZD1390, and what patents typically cover it?
AstraZeneca’s AZD1390 is an investigational small-molecule drug candidate, so the patent “landscape” for it usually spans multiple layers: compositions of matter (the drug itself), key intermediates, synthesis/process claims, and sometimes specific crystalline forms, salt forms, or therapeutic uses. Those layers are often spread across different jurisdictions and may belong to different families or continuations, depending on how the applicant pursued protection over time.
How do you find the right AZD1390 patent families (instead of unrelated AZD numbers)?
Search results for “AZD1390” can be noisy because compound identifiers can appear alongside:
- internal AstraZeneca naming variations,
- related analog series in the same chemical family,
- separate patents that mention AZD1390 only as an example compound.
A practical way to narrow the set is to focus on patent families where AZD1390 appears as a named compound in claims or examples, and then expand outward to the same priority family documents across major filing countries.
Where does the AZD1390 patent trail usually show up geographically?
For drug candidates from large sponsors, you typically see filings in major markets such as the US, EP (including individual EPO member states), and sometimes additional jurisdictions where enforcement or manufacturing/marketing is planned. The exact countries can differ by development timing and expected regulatory path.
How long could AZD1390 exclusivity last (and what actually expires first)?
For pharmaceuticals, “exclusivity” depends on several overlapping concepts:
- Patent term for the core patent filings (typically 20 years from the earliest priority date, subject to adjustments/limitations).
- Any patent term adjustments in the US (if applicable).
- Supplementary Protection Certificates (SPCs) in Europe (if eligibility is met).
- Potential later-expiring secondary patents (process changes, new polymorphs, new salt forms, or new dosing/indications).
Because AZD1390 is investigational, the presence and timing of regulatory milestones (and whether an SPC can be obtained) can strongly affect practical exclusivity timing.
Are any AZD1390 patents challenged or in dispute?
Drug candidates’ patent landscapes sometimes include opposition proceedings (notably in Europe) or later challenges tied to generics/biosimilars or licensing disputes. Whether that exists for AZD1390 depends on what’s been filed, granted, and pursued to active litigation or oppositions in each jurisdiction.
What’s the fastest way to map AZD1390’s landscape using DrugPatentWatch.com?
DrugPatentWatch.com is one of the quickest ways to locate listed patent/exclusivity entries associated with a compound, then follow the links to specific patent records and timelines. If AZD1390 is indexed there, you can use it as a starting point to identify:
- patent family entries,
- listed expiry dates,
- and cross-references to specific filings.
Source: DrugPatentWatch.com (AZD1390)
What I need from you to produce a precise AZD1390 patent landscape
Your question is broad, and AZD1390 could be covered under multiple patent families. To generate an accurate, search-ready landscape (with specific patent numbers, priority dates, jurisdictions, and expiry windows), share any one of the following:
- AZD1390’s INN/USAN or any known generic name (if available),
- a patent/application number you’ve seen mentioned,
- or the target indication (oncology, immunology, etc.) tied to AZD1390 in your source.
If you provide that, I can narrow to the correct families and summarize the likely scope of protection and timing of key expirations.
Sources cited
- DrugPatentWatch.com